Pulmozyme Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Dornase alfa, the highly purified solution of recombinant human
deoxyribonuclease I (rhDNase) produced by genetic engineering technology, was
launched in 1994 first in the U.S.A. and shortly after in 7 other countries as the first
new drug released in 30 years for the treatment of cystic fibrosis. Dornase alfa is
effective in liquefying secretions from the lungs of cystic fibrosis patients by
cleaving the extracellular DNA in purulent sputum and therefore reducing the
viscoelasticity of the secretion. It also lessens dyspnea, improves lung function,
reduces cough severity and frequency, increases the perception of well-being for
the patients with cystic fibrosis related symptoms, and has excellent safety profile.
Significant benefits have been reported in trials for the treatment of chronic
obstructive pulmonary disease and acute infectious exacerbation of chronic
bronchitis.
Verwenden
Cystic fibrosis therapy adjunct.
Pulmozyme Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
